An International Observational Study of the Safety and Efficacy of Thrombolysis in Stroke
NCT02229890 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 593
Last updated 2014-09-03
Summary
Study to evaluate the safety and efficacy of intravenous recombinant tissue Plasminogen Activator, alteplase, Actilyse® (rt-PA) (0.9 mg/kg) within 3 hours of symptom onset in acute ischemic stroke
Conditions
Interventions
- DRUG
-
alteplase
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-06-30
- Primary Completion
- 2009-03-31
More Related Trials
-
Thrombectomy Under Reopro Versus Alteplase to Treat Stoke
NCT02016547 ·Status: TERMINATED ·Phase: PHASE4
-
Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke
NCT03394950 ·Status: COMPLETED ·Phase: PHASE4
-
Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window
NCT05752916 ·Status: COMPLETED ·Phase: PHASE4
-
Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
NCT05395351 ·Status: COMPLETED
-
Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke
NCT00840671 ·Status: COMPLETED ·Phase: PHASE3
-
EXtending the Time Window for Thrombolysis in Posterior Circulation Stroke Without Early CT Signs
NCT05429476 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke
NCT02448069 ·Status: COMPLETED ·Phase: PHASE2
-
Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS
NCT03151993 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Neutrophil Extracellular Traps on Tissue Plasminogen Activator Induced Thrombolysis in Acute Ischemic Stroke Patients
NCT02907736 ·Status: WITHDRAWN
-
EXtending the tIme Window of Thrombolysis by ButyphThalide up to 6 Hours After Onset (EXIT-BT)
NCT05189509 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of Intravenous Thrombolysis for Wake-up Stroke
NCT01183533 ·Status: COMPLETED ·Phase: PHASE2
-
Rt-PA in the Treatment of Acute Ischemic Stroke
NCT00153036 ·Status: COMPLETED ·Phase: PHASE3
-
Protocol for Post Marketing Surveillance of Actilyse Vial
NCT02229799 ·Status: TERMINATED
-
Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset
NCT07094763 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Local Versus Systemic Thrombolysis for Acute Ischemic Stroke (SYNTHESIS)
NCT00540527 ·Status: COMPLETED ·Phase: PHASE3
-
24 Hours Treatment with Alteplase in Patients with Ischemic Stroke
NCT04879615 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke
NCT00790920 ·Status: COMPLETED ·Phase: PHASE3
-
Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-II）
NCT05281549 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
NCT02730455 ·Status: COMPLETED ·Phase: PHASE2
-
Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial
NCT03578822 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of a Recombinant Human Plasminogen Activator to Treat Acute Ischemic Stroke.
NCT00418275 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)
NCT03541668 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA
NCT04479449 ·Status: COMPLETED ·Phase: PHASE2
-
Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits
NCT06115070 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
NCT05700591 ·Status: COMPLETED ·Phase: PHASE3